Charles River Laboratories to Acquire Frontage’s Bioanalysis and DMPK Businesses November 9th, 2026|Business Wire| WILMINGTON, Mass.–(BUSINESS WIRE)–Charles River Laboratories to Acquire Frontage’s Bioanalysis and DMPK Businesses Please leave this field empty Subscribe to Our Newsletter We keep your data private and share your data only with third parties that make this service possible. See our Privacy Policy for more information. Please check your Inbox or Spam folder now to confirm your subscription. Like this post? Share it! FacebookXLinkedInEmail Related Posts Qureight’s Fibrosis Imaging Biomarker Selected by Contineum Therapeutics as a Secondary Endpoint in Phase 2 PROPEL-IPF Clinical Trial November 9th, 2026 | 0 Comments Kitsault Energy and Best Cure Foundation Seek Partnership in Advancing British Columbia’s Energy and Healthcare Future Under Premier-Elect Lorne Doerkson November 9th, 2026 | 0 Comments Vektor Medical Wins MedTech Innovator 2026 November 9th, 2026 | 0 Comments Compass Pathways Completes COMP360 Psilocybin New Drug Application to U.S. FDA for Treatment-Resistant Depression November 9th, 2026 | 0 Comments Avanzanite Announces Exclusive Licence Agreement to Commercialise Zemcelpro® in Europe November 9th, 2026 | 0 Comments Almirall 9M 2026 Results November 9th, 2026 | 0 Comments Virgin Active Signs Unconditional Agreement to Acquire Holmes Place Germany, Marking Its Entry Into the German Market November 9th, 2026 | 0 Comments Best’s Market Segment Report: Health and Property Lines of Business Drive Hong Kong’s Non-Life Insurance Growth November 8th, 2026 | 0 Comments Alight Appoints Vikram Kalra as India Country Leader to Advance Global Delivery and Transformation November 8th, 2026 | 0 Comments Vir Biotechnology Announces Primary Endpoint Met in Pivotal Phase 3 ECLIPSE 1 Trial for Elebsiran and Tobevibart in Chronic Hepatitis Delta November 8th, 2026 | 0 Comments Vir Biotechnology Announces Expanded Phase 2 SOLSTICE Data for Elebsiran and Tobevibart in Chronic Hepatitis Delta, Showing Deep and Sustained Viral Suppression, and Exploratory Finite Treatment Data November 8th, 2026 | 0 Comments Veradermics to Hold Conference Call to Discuss 12-Month Long-Term Results from Phase 3 ‘302’ Clinical Trial of VDPHL01 in Males with Mild-to-Moderate Pattern Hair Loss November 8th, 2026 | 0 Comments